Sevilla-Lizcano DB, Frias-Soria CL, Ortiz-Hidalgo C

Language: Spanish
References: 41
Page: 550-558
PDF size: 957.52 Kb.

ABSTRACT

Introduction: Castleman disease (CD) is a rare lymphoproliferative that comprises two distinct clinical subtypes (unicentric and multicentric) and has two basic histopathology patterns that are hyaline-vascular (HV) and plasma-cell (PC) type. Some cases of multicentric PC disease are associated with HHV-8 infection. Objective: To present the histopathologic and immunohistochemical characteristics of 39 cases of CD. Methods: A review of cases with the diagnosis CD from the files of the Department of Pathology of the ABC Medical Centre in Mexico City was performed. Thirty-nine cases of CD were identified, and a detailed paraffin immunophenotypic study of 9 of them was completed using desmin, cytokeratin OSCAR (CO) and Epidermal growth factor receptor (EGFR), to evaluate the dendritic cell population. Results and Conclusions: Of the 39 cases of CD, 24 were HV and 15 CP. All HV cases were unicentric and only one case of CP was multicentric. The most frequent localization in both subtypes was in lymph nodes; 21/24 cases in HV and 15 cases of CP. All cases were immunostained with CD20 that was expressed in the germinal centers (CGs), CD3 in the paracortical zone, and CD21 in follicular dendritic cells (CDF) within CGs, with expansion towards the area of the hyperplastic mantle zone (only in the HV variant). One case of CD CP was positive for HHV-8. Of the nine cases (6 HV and 3 PC cases) that were detailed with IHC, we found EGFR expression in FDC in all but one of the 9 cases studied and desmin was positive in fibroblastic reticulum cells (FRC) in all, but one of the cases of CD. CO was positive FRC in 3 of 6 cases of HV type and all (3) of the PC type. Clinical, histopathological and HIV and HHV-8 status markers, allow for the classification of CD into groups with markedly different outcomes and disease associations.

REFERENCES

1. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol. 2005;129 3-17.

2. Cronin DMP, Warnke RA. Castleman disease. An update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009;16:236-46.

3. Soumerai JD, Sohani AR, Abramson JS. Diagnosis and management of Castleman disease. Cancer Control. 2014;21:266-78.

4. Myloma EE, Baraboutis IG, Lekakis LJ, et al. Multicentric Castleman’s disease in HIV infection: a systematic review of the literature. AIDS Rev. 2008;10:25-35.

5. Kojima M, Nakamura N, Tsukamoto N, et al. Clinical implications of idiopathic multicentric Castleman disease among Japanese: a report of 28 cases. Int J Surg Pathol. 2008;16:391-8.

6. Uldrick TS, Polizzotto MN, Yarchoan R. Recent advances in Kaposi sarcoma herpesvirus- associated multicentric Castleman diseases. Curr Opin Oncol. 2012;24:495-505.

7. Ye B, Gao S-G, Li W, Yang L-H, Zhao S-H, Zhu X-L, et al. A retrospective study of unicentric and multicentric Castleman’s disease: a report of 52 patients. Med Oncol. 2010;27:1171-8.

8. Sun X, Chang K-C, Abruzzo LV, et al. Epidermal growth factor receptor expression in follicular dendritic cells: a shared feature of follicular dendritic cell sarcoma and Castleman’s disease. Hum Pathol. 2003;34 835-40.

9. Chan JKC, Tsang WYW. Follicular dendritic cell tumor and vascular neoplasm complicating hyaline-vascular Castleman’s Disease. Am J Surg Pathol. 1994;18:517-25.

10. Danon AD, Krishnan J, Frizzera G. Morpho-immunophenotypic diversity of Castleman’s disease, hyaline-vascular type: with emphasis on a stroma- rich variant and a new pathogenetic hypothesis. Virchows Archiv A Pathol Anat Histopathol. 1993;423:369-82.

11. Walsh-Jahnke R, Cui W, Zhang D. Late recurrence of Castleman’s disease with mixed angiomyoid, histiocytic reticulum cell, follicular dendritic cell stroma-rich proliferations: a case report and review of the literature. J Hematopathol. 2015;8:43-7.

12. Fletcher AL, Acton SE, Knoblich K. Lymph node fibroblastic reticular cells in health and disease. Nat Rev Immunol. 2015;15:350-61.

13. Bösmüller H, Klenske J, Bonzheim I, et al. Cytokeratin-positive interstitial reticulum cell tumor: recognition of a potential “in situ” pattern. Hum Pathol. 2016;49:15-21.

14. Tung KS, McCormack LJ. Angiomatous lymphoid hamartoma. Report of five cases of literature. Cancer. 1967;20:525-36.

15. Castleman B, Towne VW. Case records of the Massachusetts General Hospital weekly clinicopathological exercises: case 40011. N Engl J Med. 1954;250:26-30.

16. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer. 1956;9:822-30.

17. Festen C, Flendrig JA, Schilling PH. Giant lymphomas. Ned Tidschr Genneskd. 1969;113:1918-9.

18. Ke ler AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma cell types of giant Lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29:670-83.

19. Frizzera G, Massarelli G, Banks PM, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease. Pathological findings in 15 patients. Am J Surg Pathol. 1983;7 211-31.

20. Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;29:1646-57.

21. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86:1276-80.

22. Bonekamp D, Horton KM, Hruban RH, et al. Castleman disease: the great mimic. RadioGraphics. 2011;31:1793-807.

23. Schulte K-M, Talat N. Castleman’s disease — a two compartment model of HHV-8 infection. Nat Rev Clin Oncol. 2010;7:533-43.

24. Ioachim HL, Medeiros LJ. Lymph node pathology. 4th ed. Philadelphia: Lippincott William & Wilkins; 2009. p. 227-37.

25. Kojima M. Shimizu K, Ikota H, et al. “Follicular variant” of hyaline-vascular type of Castleman’s disease: histopathological and immunohistochemical study of 11 cases. J Clin Exp Hematopathol. 2008;48:39-45.

26. Pauwels P, Dal Cin P, Vlasveld LT, et al. A chromosomal abnormality in hyaline vascular Castleman’s disease: evidence for clonal proliferation of dysplastic stromal cells. Am J Surg Pathol. 2000;24:882-8.

27. Cokelaere K, Debiec-Rychter M, De Wolf-Peeters C, et al. Hyaline vascular Castleman’s disease with HMGIC rearrangement in follicular dendritic cells: molecular evidence of mesenchymal tumorigenesis. Am J Surg Pathol. 2002;26 662-9.

28. Chang K-C, Wang Y-C, Hung L-Y, et al. Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease. Mod Pathol. 2014;27:823-31.

29. Franke WW, Moll R. Cytoskeletal components of lymphoid organs. I. Synthesis of cytokeratins 8 and 18 and desmin in subpopulations of extrafollicular reticulum cells of human lymph nodes, tonsils, and spleen. Differentiation.1987;36;145-63.

30. Coggi G, Dell’Orto P, Braidotti P, et al. Coexpression of intermediate filaments in normal and neoplastic human tissues. Ultrastruct Pathol. 1989;13:501-14.

31. Schuerfeld K, Lazzi S, De Santi MM, et al. Cytokeratin-positive interstitial cell neoplasm: a case report and classification issues. Histopathology. 2003;43:491-4.

32. Cho J, Gong G, Choe G, et al. Extrafollicular reticulum cells in pathologic lymph nodes. J Korean Med Sci. 1994;9:9-15.

33. Van Rhee F, Stone K, Szmania S, et al. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol. 2010;8:486-98.

34. Fedoriw Y, Dogan A. The expanding spectrum of follicular lymphoma. Surg Pathol Clin. 2016;9:29-40.

35. Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122:3416-23.

36. Talat N, Schulte K-M. Castleman’s disease: systematic analysis of 416 patients from the literature. Oncologist. 2011;16:1316-24.

37. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266:1865-9.

38. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95:1406-12.

39. Gaba AR, Stein RS, Sweet DL, et al. Multicentric giant lymph node hyperplasia. Am J Clin Pathol. 1978;69:86-90.

40. Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014;123 2924-33.

41. Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet Haematol. 2016; 3:e163-75.